Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108576 · ClinicalTrials.gov registry record · Phase 3
Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)
A Phase 3 study of PTSD, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT00108576 is a Phase 3 study of PTSD that has completed, run by VA Office of Research and Development. The registered enrollment target is 101 participants, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00108576, a Phase 3 study of PTSD, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are: * To study the efficacy of divalproex in the treatment of PTSD; * To study the plasma GABA (gamma aminobutyric acid) levels before and after treatment with divalproex in PTSD.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Divalproex
Study Locations (1)
Alabama
- Tuscaloosa VA Medical Center, Tuscaloosa, AL - Tuscaloosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108576
The ClinicalTrials.gov registry entry for NCT00108576 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (66% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00108576 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00108576 about?
NCT00108576 is a clinical study titled "Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)". The purposes of this study are: * To study the efficacy of divalproex in the treatment of PTSD; * To study the plasma GABA (gamma aminobutyric acid) levels before and after treatment with divalproex in PTSD.
What is the current status of trial NCT00108576?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2003-10. Estimated completion is 2005-09.
What conditions does trial NCT00108576 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT00108576?
The interventions under investigation include: placebo (OTHER), Divalproex (DRUG).
Who is sponsoring clinical trial NCT00108576?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108576 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Low-Dose Clonidine for PTSD in Veterans
RECRUITING · Phase 3
-
Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder
COMPLETED · Phase 3
-
Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD
COMPLETED · Phase 3
-
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
COMPLETED · Phase 3
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.